Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the French version of its 2024 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers - AMF) on April 10, 2025, under number D.25-0243.

This document, available on the AMF's website (www.amf-france.org), can be viewed and downloaded (in PDF format in French and English, and in ESEF format in French only) on Transgene's website (www.transgene.fr)

It includes the following documents:

  • the Annual Financial Report;
  • the Board of Directors' Corporate Governance Report;
  • the Statutory Auditors' Reports;
  • information on the Company's share capital, including the share buyback program;
  • information on the Statutory Auditors' fees.
The Universal Registration Document also includes information on the Company's Environmental, Social and Governance (ESG) factors.

Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

Attachment